Many people consider food diet important in both prostate cancer prevention and in controlling its progression. Dietary derived agents, such as the flavonoids derived from fruits and vegetables should be of particular interest for prostate cancer survivors, as they seem to offer both chemo-prevention and an antioxidant effect along with a favorable safety and side-effect [...]
Believe it or not, in this week approaching Thanksgiving, we in the United States are faced with a second challenge to Prostate Cancer screening using the PSA test. Malecare wants you to know. The Centers for Medicare and Medicaid Services (CMS) is asking for pubic comment on a clinical quality measure that would probably [...]
On October 27, 2015, Malecare was issued patent 9,168,002 for a device and method for real time simultaneous measurement of radiation at specific parts of your body,. Understanding cumulative radiation exposure in people undergoing ionizing radiation for diagnostics and medical treatment is essential towards reducing secondary tumors from primary radiation therapy. We believe that the [...]
We have become very fortunate over the last 6 years because our arsenal of potential drugs to treat advanced, metastatic prostate cancer has grown. All of our new drugs extend life and most offer palliation of pain. As I have discussed in prior posts we are still in a quandary about how best to sequence [...]
Malecare sent questions to Albert Siu, MD, Chairperson of the U.S. Preventive Services Task Force about plans to review their 2012 recommendation against the use of the PSA test for prostate cancer screening. We thought that this information would be important since the USPTF is currently soliciting public comments on the research design of their review [...]
My good friend and fellow advocate Mike Scott (Prostate Cancer Info Link) introduced me to a new web site produced by the University of Chicago called Cost of Care (www.CostofCare.org). The site is designed around the novel idea that the cost we must pay for our cancer care has become another negative side effect or [...]
Clinical trials are vital if we expect to continue to see improvements in the treatments and medications that are available. Unfortunately, there are some historical abuses in clinical trials so many people do approach them with a level of distrust. In contemporary times the clinical trial system has many safeguards that did not exist even [...]
In an online article published Friday, November 6, 2015 Dr. David Crawford raises some very serious questions about how we standardly use hormone therapy (ADT) in the treatment of men with advanced prostate cancer. He claimed that not only is it vital for initial positive outcomes, it is vital for the successful use of the [...]
It has been long assumed that hormone therapy (ADT) used in the treatment of men with advanced prostate cancer increases a man’s risk for developing potentially live threatening thromboembolic disease (formation in a blood vessel of a clot (thrombus) that breaks loose and is carried by the blood stream to plug another vessel. The clot [...]
The Response Evaluation Criteria In Solid Tumors (RECIST) was first published in 2000 and then updated in 2009. RECIST is a set of published rules that attempt to define when cancer tumors, including prostate cancer tumors, improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. This criteria has become very important as the majority [...]
